Please activate JavaScript!
Please install Adobe Flash Player, click here for download


54. Peters S., Munoz M., Yerly S., Sanchez-Merino V., Lopez-Galindez C., Perrin L., Larder B., Cmarko D., Fakan S., Meylan P., Telenti A., 2001. Resistance to nucleo- side analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol 75:9644–9653. 55. Rasnick D., 1997. Kinetics analysis of consecutive HIV proteolytic cleavages of the Gag-Pol polyprotein. J Biol Chem 272:6348–6353. 56. Rayner M.M., Cordova B., Jackson D.A., 1997. Population dynamic studies of wild- type and drug-resistant mutant HIV in mixed infections. Virology 236:85–94. 57. Reeves J.D., Gallo S.A., Ahmad N., Miamidian J.L., Harvey P.E., Sharron M., Pohlmann S., Sfakianos J.N., Derdeyn C.A., Blumenthal R., Hunter E., Doms R.W., 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A 99:16249–16254. 58. Sawyer S.L., Emerman M., Malik H.S., 2004. Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G. PLoS. Biol. 2:E275. 59. Scherer A., Frater J., Oxenius A., Agudelo J., Price D.A., Gunthard H.F., Barnardo M., Perrin L., Hirschel B., Phillips R.E., McLean A.R., and the Swiss HIV Cohort Study, 2004. Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc. Natl. Acad. Sci. U. S. A. 60. Schmit J.C., Cogniaux J., Hermans P., Van Vaeck C., Sprecher S., Van Remoortel B., Witvrouw M., Balzarini J., Desmyter J., De Clercq E., Vandamme A.M., 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse trans- criptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 174:962–968. 61. Schock H.B., Garsky V.M., Kuo L.C., 1996. Mutational anatomy of an HIV-1 pro- tease variant conferring cross-resistanc to protease inhibitors in clinical trials. J Biol Chem 271:31957–31963. 62. Schork N.J., Gardner J.P., Zhang L., Fallin D., Thiel B., Jakubowski H., Aviv A., 2002. Genomic association/linkage of sodium lithium countertransport in CEPH pedigrees. Hypertension 40:619–628. 63. Schrofelbauer B., Chen D., Landau N.R., 2004. From The Cover: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A 101:3927–3932. 30